Smart polymers for controlled delivery of proteins and peptides: A review of patents

Recent Patents on Drug Delivery and Formulation

Volumn 3, Issue 1, 2009, Pages 40-48

  Fogueri, Laxmi R ^a   Singh, Somnath ^a  

^a CREIGHTON UNIVERSITY   (United States)

Author keywords

Aptamer; Elastin like polymer; In situ gel; Patents on smart polymers; Phase sensitive; Protein polymer bioconjugate; Protein peptide delivery; Receptor activated drug delivery system; Smart bionanoparticles; Thermosensitive

Indexed keywords

ATRIDOX; ATRIGEL; CARBOMER; CONCANAVALIN A; COPOLYMER; DOXYCYCLINE; DRUG CARRIER; GLUTARALDEHYDE; HUMAN GROWTH HORMONE; LEUPRORELIN; LIPOSOME; MICROSPHERE; PANTARIN; PEPTIDE; PLURONICS; POLOXAMER; POLOXAMERS; POLYMER; PROTEIN; REGEL; UNCLASSIFIED DRUG;

BIODEGRADABILITY; DRUG CONFORMATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; ELECTRICITY; ENZYME DEGRADATION; HEAT SENSITIVITY; HUMAN; HYDROPHOBICITY; IMMUNOGENICITY; INFECTION; IONIZATION; KINETICS; MOLECULAR WEIGHT; NANOENCAPSULATION; PAIN; PATENT; PERIODONTITIS; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; TEMPERATURE SENSITIVITY; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION ROUTE; PATIENT COMPLIANCE;

CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION ROUTES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; MEDICATION ADHERENCE; PATENTS AS TOPIC; PEPTIDES; POLYMERS; PROTEINS;

EID: 60849123435     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221109787158300     Document Type: Review

References (93)

1. Saltzman WM. Biodegradable polymers; In: Drug delivery: Engineering principles for drug therapy. New York, Oxford University Press 2001; pp. 334-350.
2. Lee HJ. Protein drug oral delivery: The recent progress. Arch Pharm Res 2002; 25: 572-584.
3. Jen A, Merkle HP. Diamonds in the rough protein crystals from a formulation perspective. Pharm Res 2001; 18: 1483-1488.
4. Degim IT, Celebi N. Controlled delivery of peptides and proteins. Curr Pharm Des 2007; 13: 99-117.
5. Bummer PM, Koppenol S. Chemical and physical considerations in protein and peptide stability; In: Protein Formulation and Delivery, Drugs and the Pharmaceutical Sciences, 99. McNally EJ, Ed. New York, Marcel Dekker 2000; pp. 15-18.
6. Dibiase MD, Kottke MK. Stability of polypeptides and proteins. Drug Stability 2000; 107: 853-874.
7. Desser L, Holomanova D, Zavadova E, Pavelka K, Mohr T, Herbacek I. Oral therapy with proteolytic enzymes decreases excessive TGF-beta levels in human blood. Cancer Chemother Pharmacol 2001; 47 (Suppl 7): 10-15.
8. Okumu FW, Cleland JL. Implants and injectables; Modified-release drug delivery technology, drugs pharm sci. In: Rathbone MJ, Hadgraft J, Roberts MS, Eds. New York, Marcel Dekker, Inc 2003; pp. 633-638.
9. Hamman JH, Enslin GM, Kotzé AF. Oral delivery of peptide drugs: barriers and developments. Bio Drugs 2005; 19: 165-177.
10. Baisley KJ, Boyce MJ, Bukofzer S, Pradhan R, Warrington SJ. Pharmacokinetics, safety and tolerability of three dosage regimens of buccal adhesive testosterone tablets in healthy men suppressed with leuprorelin. J Endocrinol 2002; 175: 813-819.
11. Shahiwala A, Misra A. Preliminary investigation of the nasal delivery of liposomal leuprorelin acetate for contraception in rats. J Pharm Pharmacol 2006; 58: 19-26.
12. Mingda B, Singh J. Degradation of luteinizing hormone releasing hormone in buccal, liver, nasal and skin tissues. Int J Pharm 1998; 175: 269-273.
13. Shoyele SA. Controlling the release of proteins/peptides via the pulmonary route. Methods Mol Biol 2008; 437: 141-148.
14. Schuetz YB, Naik A, Guy RH, Kalia YN. Emerging strategies for the transdermal delivery of peptide and protein drugs. Expert Opin Drug Deliv 2005; 2: 533-548.
15. Cao X, Gibbs ST, Fang L, et al. Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res 2006; 23: 1675-1686.
16. Lu Y, Yu Y, Tang X. Sucrose acetate isobutyrate as an in situ forming system for sustained risperidone release. J Pharm Sci 2007; 96: 3252-3262.
17. Packhaeuser CB, Kissel T. On the design of in situ forming biodegradable parenteral depot systems based on insulin loaded dialkylaminoalkyl-amine-poly(vinyl alcohol)-g-poly(lactide-coglycolide) nanoparticles. J Control Rel 2007; 123: 131-140.
18. Singh S, Singh J. Controlled release of a model protein lysozyme from phase sensitive smart polymer systems. Int J Pharm 2004; 271: 189-196.
19. Berkland C, Pollauf E, Raman C, Silverman R, Kim K, Pack DW. Macromolecule release from monodisperse PLG microspheres: Control of release rates and investigation of release mechanism. J Pharm Sci 2007; 96: 1176-1191.
20. Rawat M, Singh D, Saraf S, Saraf S. Lipid carriers: A versatile delivery vehicle for proteins and peptides. Yakugaku Zasshi 2008; 128: 269-280.
21. Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 2008; 60: 876-885.
22. Piras AM, Chiellini F, Fiumi C, et al. A new biocompatible nanoparticle delivery system for the release of fibrinolytic drugs. Int J Pharm 2008; 357: 206-271.
23. Shantha Kumar TR, Soppimath K, Nachaegari SK. Novel delivery technologies for protein and peptide therapeutics. Curr Pharm Biotech 2006; 7: 261-276.
24. Chen S, Singh J. Controlled release of growth hormone from thermosensitive triblock copolymer systems: in vitro and in vivo Evaluation. Int J Pharm 2008; 352: 58-65.
25. Bala I, Hariharan S, Kumar MN. PLGA nanoparticles in drug delivery: the state of the art. Crit Rev Ther Drug Carrier Syst 2004; 21: 387-422.
26. Vasir JK, Labhasetwar V. Targeted drug delivery in cancer therapy. Technol Cancer Res Treat 2005; 4: 363-374.
27. Chiellini F, Bartoli C, Dinucci D, Piras AM, Anderson R, Croucher T. Bioeliminable polymeric nanoparticles for proteic drug delivery. Int J Pharm 2007; 343: 90-97.
28. Escalona-Benz E, Benz MS, Murray TG, et al. Magnetically integrated microporous implant: safety and efficacy of secondary posting. Arch Ophthalmol 2003; 121: 1596-1600.
29. Milovancev M, Muir P, Manley PA, Seeherman HJ, Schaefer S. Clinical application of recombinant human bone morphogenetic protein-2 in 4 dogs. Vet Surg 2007; 36: 132-140.
30. Heath F, Haria P, Alexander C. Varying polymer architecture to deliver drugs. AAPS J 2007; 9: E235-40.
31. Soppimath KS, Aminabhavi TM, Dave AM, Kumbar SG, Rudzinski W. Stimulus-Responsive "Smart" hydrogels as novel drug delivery systems. Drug Dev Ind Pharm 2002; 28: 957-974.
32. Sophie R. Tomme V, Storm G, Hennink WE. In situ Gelling hydrogels for pharmaceutical and biomedical applications. Int J Pharm 2008; 355: 1-18.
33. Hatefi A, Amsden B. Biodegradable injectable in situ forming drug delivery systems. J Control Release 2002; 80: 9-28.
34. Chung HJ, Lee Y, Park TG. Thermosensitive and biodegradable hydrogels based on stereocomplexed Pluronic multi-block copolymers for controlled protein delivery. J Control Release 2008; 127: 22-30.
35. Wasan K, Subramanian R, Kwong M, Goldberg I, Wright T, Johnston T. Poloxamer 407-mediated alterations in the activities of enzymes regulating lipid metabolism in rats. J Pharm Sci 2003; 6: 189-197.
36. Ma WD, Xu H, Nie SF, Pan WS. Temperature-responsive, pluronicg-poly(acrylic acid) copolymers in situ gels for ophthalmic drug delivery: rheology, in vitro drug release, and in vivo resident property. Drug Dev Ind Pharm 2008; 34: 258-266.
37. Barichello JM, Morishita M, Takayama K, Nagai T. Absorption of insulin from Pluronic F-127 gels following subcutaneous administration in rats. Int J Pharm 1999; 184: 189-198.
38. Wenzel J, Balaji K, Koushik K, et al. Pluronic F127 gel formulations of deslorelin and GnRH reduce drug degradation and sustain drug release and effect in cattle. J Control Release 2002; 85: 51-59.
39. Paavola A, Kilpelainen I, Yliruusi J, Rosenberg P. Controlled release injectable liposomal gel of ibuprofen for epidural analgesia. Int J Pharm 2000; 199: 85-93.
40. Zhang L, Parsons D, Navarre C, Kompella U. Development and in vitro evaluation of sustained release poloxamer 407 (P407) gel formulations of ceftiofur. J Control Release 2002; 85: 73-81.
41. Choi S, Baudys M, Kim SW. Control of blood glucose by novel GLP-1 delivery using biodegradable triblock copolymer of PLGAPEG-PLGA in type 2 diabetic rats. Pharm Res 2004; 21: 827-831.
42. Choi S, Kim SW. Controlled release of insulin from injectable biodegradable triblock copolymer depot in ZDF rats. Pharm Res 2003; 20: 2008-2010.
43. Chen S, Singh J. Controlled delivery of testosterone from smart polymer solution based system: in vitro Evaluation. Int J Pharm 2005; 295: 183-190.
44. Chen S, Singh J. in vitro Release of levonorgestrel from phase sensitive and thermosensitive smart polymer delivery systems. Pharm Dev Technol 2005; 10: 319-325.
45. Qiao M, Chen D, Hao T, Zhao X, Hu H, Ma X. Effect of bee venom peptide-copolymer interactions on thermosensitive hydrogel delivery systems. Int J Pharm 2007; 345: 116- 124.
46. Dreher MR, Liu W, Michelich CR, Dewhirst MW, Chilkoti A. Thermal cycling enhances the accumulation of a temperature -sensitive biopolymer in solid tumors. Cancer Res 2007; 67: 4418-4424.
47. Hart DS, Gehrke SH. Thermally associating polypeptides designed for drug delivery produced by genetically engineered cells. J Pharm Sci 2007; 96: 484 -516.
48. Kempe S, Metz H, Bastrop M, Hvilsom A, Contri RV, Mäder K. Characterization of thermosensitive chitosan-based hydrogels by rheology and electron paramagnetic resonance spectroscopy. Eur J Pharm Biopharm 2008; 68: 26-33.
49. Ji-Yeon S, Yong JJ, Byong MK, Yong MP, Youn SS. Synthesis and characterization of biocompatible poly(organophosphazenes) aiming for local delivery of protein drugs. Int J Pharm 2006; 314: 90-96.
50. Singh S, Singh J. Controlled release of a model protein lysozyme from phase sensitive smart polymer systems. Int J Pharm 2004; 271: 189-196.
51. Kranz H, Bodmeier R. A novel in situ forming drug delivery system for controlled parenteral drug delivery. Int J Pharm 2007; 332: 107-114.
52. Dong WY, Körber M, Löpez Esguerra V, Bodmeier R. Stability of poly(D,L-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems. J Control Release 2006; 115: 158-167.
53. Kang F, Singh J. in vitro Release of insulin and biocompatibility of in situ forming gel systems. Int J Pharm 2005; 304: 83-90.
54. Al-Tahami K, Meyer A, Singh J. Poly lactic acid based injectable delivery systems for controlled release of a model protein, lysozyme. Pharm Dev Technol 2006; 11: 79-86.
55. Sartor O. Leuprolide acetate in a novel sustained-release delivery system. Urology 2003; 61: 25-31.
56. Dunn, R.L., Garrett, J.S., Ravivarapu, H., Chandrashekar, B.L.: US20070104759 (2007).
57. Ravivarapu HB, Moyer KL, Dunn RL. Sustained suppression of pituitary- gonadal axis with an injectable, in situ forming implant of leuprolide acetate. J Pharm Sci 2000; 89: 732-741.
58. Chu FM, Jayson M, Dineen MK, Perez R, Harkaway R, Tyler RC. A clinical study of 22.5 mg La-2550: A new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2002; 168: 1199-1203.
59. Higuchi T. Mechanism of sustained-action medication. J Pharm Sci 1963; 52: 1145-1149.
60. Royals MA, Fujita SM, Yewey GL, Rodriguez J, Schultheiss PC, Dunn RL. Biocompatibility of a biodegradable in situ forming implant system in rhesus monkeys. J Biomed Mater.Res 1999; 45: 231-239.
61. Bromberg L. Intelligent polyelectrolytes and gels in oral drug delivery. Curr Pharm Biotechnol 2003; 4: 339-349.
62. Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv Rev 2001; 53: 321-339.
63. Sajeesh S, Sharma CP. Novel polyelectrolyte complexes based on poly(methacrylic acid)-bis(2-aminopropyl)poly(ethylene glycol) for oral protein delivery. J Biomater Sci Polym Ed 2007; 18: 1125-1139.
64. Jeong B, Gutowska A. Lessons from nature: Stimuli-responsive polymers and their biomedical applications. Trends Biotechnol 2002; 20: 305-311.
65. Sajeesh S, Sharma CP. Novel pH responsive polymethacrylic acidchitosan-polyethylene glycol nanoparticles for oral peptide delivery. J Biomed Mater.Res B Appl Biomater 2006; 76: 298-305.
66. Bulmus V, Ding Z, Long CJ, Stayton PS, Hoffman AS. Site-specific polymer-streptavidin bioconjugate for pH-controlled binding and triggered release of biotin. Bioconjug Chem 2000; 11: 78-83.
67. Morishita M, Lowman AM, Takayama K, Nagai T, Peppas NA. Elucidation of the mechanism of incorporation of insulin in controlled release systems based on complexation polymers. J Control Release 2002; 81: 25-32.
68. Peppas NA. Devices based on intelligent biopolymers for oral protein delivery. Int J Pharm 2004; 277: 11-17.
69. Zhang K, Wu XY. Temperature and pH-Responsive polymeric composite membranes for controlled delivery of proteins and peptides. Biomaterials 2004; 22: 5281-5291.
70. Breuniga M, Bauera S, Goepferich A. Polymers and nanoparticles: Intelligent tools for intracellular targeting. Eur J Pharm Biopharm 2008; 68: 112-128.
71. George M, Abraham TE. pH Sensitive alginate-guar gum hydrogel for the controlled delivery of protein drugs. Int J Pharm 2007; 335: 123-129.
72. Henry SM, El-Sayed ME, Pirie CM, Hoffman AS, Stayton PS. pH-Responsive poly(styrene-alt-maleic anhydride) alkylamide copolymers for intracellular drug delivery. Biomacromolecules 2006; 7: 2407-2414.
73. Stayton PS, El-Sayed ME, Murthy N, et al. 'Smart' delivery systems for biomolecular therapeutics. Orthod Craniofac Res 2005; 8: 219-225.
74. Brahim S, Narinesingh D, Guiseppi-Elie A. Bio-smart hydrogels: Co-joined molecular recognition and signal transduction in biosensor fabrication and drug delivery. Biosens Bioelectron 2002; 17: 973-981.
75. Kim JJ, Park K. Modulated insulin delivery from glucose-sensitive hydrogel dosage forms. J Control Release 2001; 77: 39-47.
76. Kashyap N, Viswanad B, Sharma G, Bhardwaj V, Ramarao P, Ravi KMN. Design and evaluation of biodegradable, biosensitive in situ gelling system for pulsatile delivery of insulin. Biomaterials 2007; 28: 2051-2060.
77. Chourasia MK, Jain SK. Polysaccharides for colon targeted drug delivery. Drug Deliv 2004; 111: 29-48.
78. Arora S, Ali J, Ahuja A, Khar RK, Baboota S. Floating drug delivery systems: A Review. AAPS Pharm Sci Tech 2005; 6: E372-E90.
79. Ugurlu T, Turkoglu M, Gurer US, Akarsu BG. Colonic delivery of compression coated nisin tablets using pectin/HPMC polymer mixture. Eur J Pharm Biopharm 2007; 67: 202-210.
80. Venkatesh, S., Wower, J., Byrne, M.E.: US20080138408 (2008).
81. Cubicciotti, R.S.: US20077238361 (2007).
82. Vitaliano, F., Vitaliano, G.: US20087393924 (2008).
83. Caneba, G.T., Tirumala, V.R., Mancini, D.C., Wang, H.: US20056869983 (2005).
84. Lin, C., Chen, I., Lui, W.: US20046765081 (2004).
85. Samra, B., Galaev, I., Mattiasson, B.: US20036538089 (2003).
86. Cubicciotti, R.S.: US20016287765 (2001).
87. Kim MS, Seo KS, Khang G, Cho SH, Lee HB. Preparation of poly(ethylene glycol)-block-poly(caprolactone) copolymers and their applications as thermo-sensitive materials. J Biomed Mater.Res A 2004; 70: 154-158.
88. Sosnik A, Cohn D. Reverse thermo-responsive poly(ethylene oxide) and poly(propylene oxide) multiblock copolymers. Biomaterials 2004; 26: 349-357.
89. Koji Y, Akinori K, Toshihide I, Timothy E. Long thermoreversible polyesters consisting of multiple hydrogen bonding (MHB). Macromolecules 2004; 37: 3519-3522.
90. Bidwell GL, Raucher D. Application of thermally responsive polypeptides directed against c-Myc transcriptional function for cancer therapy. Mol Cancer Ther 2005; 4: 1076-1085.
91. Furgeson, D.Y., Bae, Y.: US20070265197 (2007).
92. Stayton, P.S., Hoffman, A.S., Malmstadt, N., Shimoboji, T.T., Kulkarni, S.: US20060127925 (2006).
93. Lowe, T.L., Kim, Y.S., Huang, X.: US20050169882 (2005).